SIDE-BY-SIDE EVIDENCE

Compare evidence.
Keep the context.

Select 2–3 profiles from the English Library. Class and grade describe evidence and regulatory context, not comparative effectiveness or suitability for an individual.

Choose profiles

SIDE-BY-SIDE EVIDENCE VIEW

Compare selected profiles

Evidence comparison · not a treatment ranking

Evidence boundaries, not cross-trial treatment outcomes
Molecule	Flibanserin	PT-141 (Bremelanotide)	Sildenafil
Research Topic	Clinical / Endocrine Pharmacology	Sexual Medicine Pharmacology	Sexual Medicine Pharmacology
Pharmacology	Serotonergic medicine approved for a narrowly defined HSDD population	Cyclic heptapeptide / melanocortin receptor agonist	Phosphodiesterase type 5 (PDE5) inhibitor
PrimeCore Class	Class AApproved in a bounded context	Class AApproved in a bounded context	Class AApproved in a bounded context
Evidence Grade	Grade AStrong regulatory + clinical evidence	Grade AStrong regulatory + clinical evidence	Grade AStrong regulatory + clinical evidence
Evidence boundary	Flibanserin is classified here as Serotonergic medicine approved for a narrowly defined HSDD population. Controlled evidence and labeling apply to defined women with acquired, generalised HSDD after exclusion of other causes. FDA-authorised prescription product labeling exists for a bounded population; approval is not global and supplier tablets are unverified. A catalogue name does not establish identity, formulation, quality or authorisation, and this page provides no dosage, mixing, injection or purchasing instructions.	PT-141 is a development code for bremelanotide. FDA approval applies to the specific Vyleesi product for acquired, generalized HSDD in defined premenopausal women—not to men, performance enhancement or every online PT-141 product.	A PDE5 inhibitor with separate approved products for erectile dysfunction and pulmonary arterial hypertension; molecule identity does not make brands, formulations or indications interchangeable.
Unknowns	Insufficient data in the current dataset	Insufficient data in the current dataset	English translation is not yet verified for 3 excerpt(s). This is a language gap, not an absence of risks or uncertainty. Read original excerpts (Thai / mixed language) Viagra ไม่ใช่ชื่อแทน sildenafil ทุกผลิตภัณฑ์ หลักฐาน ED ไม่ใช้ยืนยันประโยชน์ PAH ของสูตรอื่นโดยอัตโนมัติ ไม่ใช่ยากระตุ้นความต้องการทางเพศและไม่ป้องกันโรคติดต่อทางเพศสัมพันธ์
Limitations	Flibanserin molecule or active moiety ≠ ester/salt ≠ formulation ≠ brand ≠ supplier product; biological plausibility or historical use ≠ current approval ≠ safe performance use	The pivotal evidence concerns a narrowly defined group of predominantly U.S. premenopausal women and uses patient-reported desire and distress endpoints. It does not answer efficacy or safety questions for men, postmenopausal women, general libido enhancement, erectile dysfunction, performance or unverified formulations. A later methodological critique characterised several observed effects as small and questioned some outcome-measure validity; this does not reverse FDA approval but is relevant to interpreting effect size and certainty.	Insufficient data in the current dataset
Sources	DailyMed · Flibanserin human drug-label inventory FDA · Why unapproved drugs require product-specific review WADA · 2026 Prohibited List	https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210557Orig1s000MultidisciplineR.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/210557Orig1s000ltr.pdf https://pubmed.ncbi.nlm.nih.gov/31599840/ https://pubmed.ncbi.nlm.nih.gov/36809187/ https://www.accessdata.fda.gov/cms_ia/importalert_190.html https://precision.fda.gov/ginas/app/ui/substances/be0ce9ff-94bb-4761-9658-5c5a0a59b6ce https://www.ema.europa.eu/en/medicines https://products.mhra.gov.uk/ https://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf	Thai FDA — Viagra product record DailyMed — sildenafil ED label U.S. FDA — Revatio prescribing information EAU — Management of erectile dysfunction
Read more	Read English overview Complete evidence profile (Thai)	Read English overview Complete evidence profile (Thai)	Read English overview Complete evidence profile (Thai)

This table does not compare doses, cross-trial outcomes or individual suitability. Missing information does not establish an absence of risk.

Choose another comparison

Continue reading

Missing fields mean information is unavailable in the current structured dataset, not that a molecule has no risks or uncertainties. English translations retain the original evidence boundaries. Where translation is not yet verified, the original Thai excerpts remain available under an explicit label. Sources retain their original language.

10 questions before drawing conclusions

Compare evidence.Keep the context.

Continue reading

Contact PrimeCoreBio

Compare evidence.
Keep the context.